Get the Stockscreener App
505.75
2.07%
-10.69
Vertex Pharmaceuticals Inc stock is traded at $505.75, with a volume of 1.13M.
It is down -2.07% in the last 24 hours and up +6.18% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$516.44
Open:
$511.41
24h Volume:
1.13M
Relative Volume:
0.73
Market Cap:
$128.19B
Revenue:
$12.34B
Net Income/Loss:
$4.34B
P/E Ratio:
29.98
EPS:
16.8685
Net Cash Flow:
$3.71B
1W Performance:
+1.95%
1M Performance:
+6.18%
6M Performance:
+2.91%
1Y Performance:
+29.58%
1-Day Range:
$502.29
$513.64
1-Week Range:
$502.29
$546.17
52-Week Range:
$374.17
$546.17
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Upgrade | Maxim Group | Hold → Buy |
| Mar-10-26 | Initiated | Jefferies | Buy |
| Mar-10-26 | Reiterated | Oppenheimer | Outperform |
| Feb-13-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough? - Yahoo Finance
Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near? - Yahoo Finance
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - The Motley Fool
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance - Yahoo Finance
Vertex-Crinetics pharma merger cleared in US, Germany, Austria, Australia - MLex
Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade) - Seeking Alpha
Crinetics Pharmaceuticals merger with Vertex Pharmaceuticals advances after regulatory clearances - Investing.com
Crinetics Pharmaceuticals (CRNX) advances Vertex merger after key antitrust milestones - Stock Titan
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - fortune.com
Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says - marketscreener.com
RBC Capital reiterates Vertex stock rating on pipeline outlook By Investing.com - Investing.com Canada
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO) - theglobeandmail.com
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $558 to $633 - Moomoo
Fierce Biotech Layoff Tracker 2026: Aura loses 20% of staffers; aTyr shrinks by 60% - Fierce Biotech
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and MoonLake Immunotherapeutics (MLTX) - theglobeandmail.com
Bernstein reiterates Vertex stock rating on cystic fibrosis outlook By Investing.com - Investing.com Canada
Bernstein reiterates Vertex stock rating on cystic fibrosis outlook - Investing.com
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - Yahoo Finance
Vertex Pharma stock added to BofA US 1 list of top ideas - Investing.com South Africa
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Handelsbanken Fonder AB - MarketBeat
Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating - marketscreener.com
Vertex Pharmaceuticals Faces New Competitive Threats - Intellectia AI
VERTEX PHARMACEUTICALS INCORPORATED : JEFFERIES RAISES TARGET PRICE TO $633 FROM $610 - Bitget
Why Vertex Pharma Popped, As A Key Rival Plummeted 92% - Investor's Business Daily
Wolfe Research raises Vertex stock price target on CF franchise value - Investing.com
Wall Street Analysts Are Neutral on Top Healthcare Picks - theglobeandmail.com
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex - biopharmadive.com
Vertex's would-be rival Sionna scraps cystic fibrosis drug add-on after trial flop - FirstWord Pharma
Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial - TipRanks
Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails - TradingView
Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial - STAT
Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its PipelineHas The Bull Case Changed? - Yahoo Finance
Vertex Pharmaceuticals (NASDAQ:VRTX) Hits New 52-Week HighStill a Buy? - MarketBeat
Why is Vertex Pharmaceuticals stock surging today? By Investing.com - Investing.com South Africa
Vertex Pharmaceuticals stock hits all-time high at 539.99 USD By Investing.com - Investing.com Australia
Vertex Pharmaceuticals Inc Stock (VRTX) Opened Up by 9.76% on Aug 10: What Investors Need To Know - tradingkey.com
Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex - Fierce Biotech
Vertex Pharmaceuticals stock hits all-time high at 539.99 USD - Investing.com
SpaceX, AAON, Vertex Pharma - TradingView
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Leader with 12.74% Potential Upside - DirectorsTalk Interviews
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? - AOL.com
Vertex Pharmaceuticals Inc Stock Price Live, Charts & NewsThe Economic Times - The Economic Times
Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday - AOL.com
Vertex Pharmaceuticals Incorpor (VRTX) Stock forecasts - sg.finance.yahoo.com
Vertex Pharmaceuticals Incorpor (VRTX) Stock Forecasts - Yahoo! Finance Canada
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Beacon Investment Advisory Services Inc. - MarketBeat
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Czech National Bank - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):